EPN
Mallard duck (Anas platyrhynchos)
Chemical | Endpoint Value | Endpoint Description | Sex | Life Cycle Stage | Sample Size | Location | Type | Age-Specific | Lab |
---|---|---|---|---|---|---|---|---|---|
EPN | decreased @ 12, 36 ug/g | brain weight, protein content, acetylcholinesterase and neurotoxic esterase versus controls | Not Reported | Hatchling | 12/group | Toxicity Factor Datasets | 72 hr of incubation (time of treatment) | Laboratory | |
EPN | decreased @ 12 ug/g (82%); 36 ug/g (77%); 108 ug/g (70%) | percent survival versus controls | Not Reported | Embryo | 10/group | Toxicity Factor Datasets | 72 hr of incubation (time of treatment) | Laboratory | |
EPN | decreased @ 12, 36, 108 ug/g | brain weight, acetylcholinesterase activity, neurotoxic esterase activity versus controls | Not Reported | Embryo | 10/group | Toxicity Factor Datasets | 72 hr of incubation (time of treatment) | Laboratory | |
EPN | decreased @ 108 ug/g | brain protein content versus controls | Not Reported | Embryo | 10/group | Toxicity Factor Datasets | 72 hr of incubation (time of treatment) | Laboratory | |
EPN | decreased @ 36 (cholineserase only), 108 ug/g | plasma alkaline phosphatase, aspartate aminotransferase, cholinesterase activities, and uric acid | Not Reported | Embryo | 12/group | Toxicity Factor Datasets | 72 hr of incubation (time of treatment) | Laboratory | |
EPN | decreased @ 12, 36, 108 ug/g | embryo weight and length, % normal survivors versus controls | Not Reported | Embryo | 12/group | Toxicity Factor Datasets | 72 hr of incubation (time of treatment) | Laboratory | |
EPN | decreased @ 12 ug/g (48%), 36 ug/g (29%), 108 ug/g (0%) | % surviving to hatch versus controls | Not Reported | Hatchling | 12/group | Toxicity Factor Datasets | 72 hr of incubation (time of treatment) | Laboratory | |
EPN | decreased @ 12, 36 ug/g | plasma cholinesterase activity, hemoglobin and uric acid content | Not Reported | Hatchling | 12/group | Toxicity Factor Datasets | 72 hr of incubation (time of treatment) | Laboratory |
Chemical | Endpoint Value | Endpoint Description | Sex | Life Cycle Stage | Sample Size | Location | Type | Age-Specific | Lab |
---|---|---|---|---|---|---|---|---|---|
EPN | decreased @ 90, 270 ppm | food consumption and body weight compared with controls | Female | Juvenile | 6/group | Toxicity Factor Datasets | 20 wks | Laboratory | |
EPN | increased @ all doses | incidence of hyperactivity, ataxia, and/or paralysis compared with controls | Female | Juvenile | 6/group | Toxicity Factor Datasets | 20 wks | Laboratory | |
EPN | increased @ 30, 90, 270 ppm | incidence of CNS lesions (demyelination, axonal degeneration in spinal cord) compared with controls | Female | Juvenile | 6/group | Toxicity Factor Datasets | 20 wks | Laboratory | |
EPN | decreased @ all doses | activity of brain and plasma cholinesterase, and brain neurotoxic esterase compared with controls | Female | Juvenile | 6/group | Toxicity Factor Datasets | 20 wks | Laboratory | |
EPN | decreased @ 90, 270 pmm | plasma alkaline phosphatase activity compared with controls | Female | Juvenile | 6/group | Toxicity Factor Datasets | 20 wks | Laboratory |
American Kestrel (Falco sparverius)
Chemical | Endpoint Value | Endpoint Description | Sex | Life Cycle Stage | Sample Size | Location | Type | Lab |
---|---|---|---|---|---|---|---|---|
EPN | 4.0 mg/kg bw (3.1-5.1 95% CI) | LD50 | Both Male and Female | Adult | 5/group | Toxicity Factor Datasets | Laboratory | |
EPN | 68% (10.0 SD) | mean brain cholinesterase depression (relative to control) in birds that died in 8 hrs post-dose | Both Male and Female | Adult | 12 | Toxicity Factor Datasets | Laboratory |